With approval for Tresiba in China potentially years out, Novo Nordisk expects continued price competition from domestic firms that will show up on the books more widely in the coming year and into 2017.
China Resources Pharmaceutical Group, part of the state-owned mega-corporation China Resources is planning to tap the capital markets in Hong Kong for a $1 billion initital public offering, according to a report by Reuters.
GlaxoSmithKline saw another sharp drop in China sales of established pharmaceuticals, but CEO Andrew Witty said that was all part-and-parcel of reshaping the business including sales of products in the Middle Kingdom and that 2016 should start to see a turnaround, along with emerging markets generally.
China once again aided AstraZeneca, with the full-year sales up 15%, the same pace as Latin America, and up 10% on the fourth quarter.
A $774 million deal Hong Kong-listed Sino Biopharmaceutical planned to make by buying a stake in a Chinese asset management company has been axed by Sino after markets around the world have fallen, especially in China.
Beijing-based Sinovac Biotech is in play, with the board getting an unsolicited offer of $7 a share from a consortium of Chinese drug and investment firms, placing it 13% above a management-led offer of $6.18 a share days before for a firm that has a small, but growing, vaccine business in China.
China-focused SciClone Pharmaceuticals is reviewing a range of "strategic alternatives" to enhance shareholder value fresh off a settlement with the U.S. Securities and Exchange Commission on possible violations of the Foreign Corrupt Practices Act, or FCPA.
Pfizer came through a hectic fourth quarter with a major deal pending and at work on integrating an earlier one while at the same time trying to identify niches for both in emerging markets and particularly China.
An application by a team led by pharmacologist and Nobel Prize laureate Tu Youyou for clinical trials using antimalarial drug artemisinin to treat autoimmune inflammatory disease lupus is under review by China FDA, China.org.cn said.
Shanghai-based Qiming Venture Partners raised $648 million in commitments for its fifth U.S. dollar venture capital fund, putting its assets under management at $2.5 billion since a debut in 2006 to focus on a mix of China healthcare-related firms among other investments such as mobile phone maker Xiaomi, the company said in a release.